Vilon (KE Dipeptide): The Russian Immune Bioregulator That Modulates SIRT1 and Telomerase

The idea that a dipeptide (just two amino acids linked together) could modulate the expression of SIRT1, PARP1, TERT, and FOXO1 simultaneously in aging human cells sounds implausible. But that is what published research from Khavinson's group shows, and understanding how this might work requires understanding the core concept behind the short peptide bioregulator theory.

Short peptides are not just amino acid chains. They are signaling molecules that can enter cells through peptide transporters (PEPT1, PEPT2, LAT family transporters), travel to the nucleus, and interact with gene regulatory elements including histones and transcription factors. The 2023 Biomolecules paper from Khavinson's group (PMID 36979488) directly analyzed the transport feasibility of 26 short bioactive peptides and confirmed that KE and related dipeptides have the transporter compatibility required to reach intracellular targets.

Once inside aging cells, KE appears to interact with chromatin in a way that shifts gene expression toward patterns associated with younger cells. The specific mechanism is still being characterized, but the gene expression data is concrete and published in English-language peer-reviewed journals, making this accessible to Western researchers in a way that most of the Khavinson literature is not.

The most important published study for Western researchers to understand Vilon's mechanistic basis is Ashapkin et al. 2020 (PMID 32399807) in Molecular Biology Reports. This study used human embryo bone marrow mesenchymal stem cells (FetMSCs) at different passage numbers to model in vitro aging, then treated cells with three short peptides: AED (Ala-Glu-Asp), KED (Lys-Glu-Asp), and KE (Lys-Glu, Vilon).

The gene expression endpoints measured by quantitative RT-PCR were: - IGF1 (insulin-like growth factor 1): key anabolic and anti-aging signal - FOXO1 (forkhead box O1): major SIRT1 downstream target, regulates cell survival - TERT (telomerase reverse transcriptase): catalytic component of telomerase - TNKS2 (tankyrase 2): regulates telomere length through tankyrase activity - NFkB (nuclear factor kappa B): master inflammatory transcription factor

Results: All three peptides produced statistically significant changes in multiple longevity gene expression levels in aged FetMSCs. KE (Vilon) specifically upregulated TERT and modulated FOXO1 expression in aged cells. The effects were most pronounced in highly aged cell populations, suggesting these peptides specifically address age-related gene expression dysregulation rather than affecting all cells uniformly.

This is direct English-language evidence that a Russian-developed dipeptide modulates the core genes of the longevity science field in human cells.

The 2023 paper (PMID 37782636) adds a crucial layer to the Vilon mechanism. This study showed that KE specifically regulates SIRT1, PARP1, and PARP2 in aging human mesenchymal stem cells, and the implications are significant.

SIRT1, PARP1, and PARP2 are all NAD+-consuming enzymes that compete for the same cofactor pool. SIRT1 uses NAD+ to perform its longevity-promoting deacylation functions. PARP1 and PARP2 use NAD+ for DNA repair, which is essential but becomes pathologically excessive in cells with accumulated DNA damage. In aged cells, PARP overactivation can deplete NAD+ to levels where SIRT1 becomes substrate-limited.

If KE (Vilon) modulates the expression balance between SIRT1 and PARP1/PARP2, it could shift this competition in favor of sirtuin activity without requiring exogenous NAD+ repletion. This is a mechanistically distinct approach to the same problem that NAD+ precursors address: improving the NAD+/sirtuin axis. NAD+ precursors increase the substrate supply; Vilon may instead shift the competitive balance of enzymes consuming it.

For researchers interested in sirtuin biology and NAD+ metabolism, Vilon is a potentially powerful tool for mechanistic studies that has barely appeared in Western research literature.

Vilon was developed as an immune system bioregulator before its molecular mechanisms were characterized. The original clinical rationale was that thymic involution with aging causes a progressive decline in T-cell function, and that thymic-derived peptides could restore this function.

Published Russian clinical data on Vilon (primarily in Russian-language journals) documents: restoration of T-cell subset ratios (CD4+/CD8+) in elderly patients, improved natural killer cell activity, normalized cytokine production profiles, and improved humoral immune responses in aged subjects.

The immune data from Vilon overlaps significantly with the immune data from Thymalin (the other Khavinson thymic bioregulator, which is a polypeptide mixture rather than a pure dipeptide). The distinction is mechanistic precision: Vilon as a defined KE dipeptide can be studied with complete structural certainty, while Thymalin's polypeptide mixture composition introduces variables that make mechanistic attribution more complex.

For researchers studying immunosenescence (the age-related decline of immune function), Vilon offers a tool with both Russian clinical evidence and recently characterized molecular mechanisms.

Vilon (KE dipeptide, Lys-Glu) can be precisely synthesized by any peptide synthesis facility, and the simple structure (just two amino acids) means there are no complex stereocenters or post-translational modifications to worry about. The molecular weight is 275.3 Da (Lys-Glu), making it one of the smallest and most well-defined research peptides.

For cell culture studies: The published Ashapkin 2020 protocol used KE at 1 ng/mL, 10 ng/mL, and 100 ng/mL concentrations in aging FetMSC cultures, with 72-hour treatment before gene expression analysis. These concentrations are extremely low and well within what standard peptide solutions can achieve.

For comparison with other longevity compounds: Combining KE treatment with NAD+ precursors in aging cell cultures would allow mechanistic dissection of whether KE's SIRT1 regulatory effects are additive, redundant, or complementary to substrate-level NAD+ repletion. This experiment has not been published and represents an open mechanistic question.

Vilon is not currently stocked by Blackwell BioLabs as a product, but Epithalon (the pineal gland bioregulator from the same system) is available for longevity research, and the published KE/TERT mechanistic data is directly relevant to understanding Epithalon's mechanism in the same gene regulatory framework.